Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Solnerstotug (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sensei Biotherapeutics

    • Most Recent Events

    • 27 Mar 2025 According to a Sensei Biotherapeutics media release, Dr. Shiraj Sen, is an investigator in the Phase 1/2 study.
    • 27 Mar 2025 According to a Sensei Biotherapeutics media release, company will host an investor webcast today at 5:30 p.m. ET.
    • 27 Mar 2025 According to a Sensei Biotherapeutics media release, company plans to initiate a Phase 2 study in Q1 2026,with the trial design and patient selection strategies to be informed by the ongoing dose expansion results. Further analyses, including biomarker-based patient selection, are underway to optimize the Phase 2 design.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top